- Home
- NA vs RPID Comparison
NA vs RPID Comparison
Compare NA & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- RPID
- Stock Information
- Founded
- NA 2019
- RPID 2006
- Country
- NA China
- RPID United States
- Employees
- NA N/A
- RPID N/A
- Industry
- NA Semiconductors
- RPID Medical Specialities
- Sector
- NA Technology
- RPID Health Care
- Exchange
- NA Nasdaq
- RPID Nasdaq
- Market Cap
- NA 95.7M
- RPID 106.5M
- IPO Year
- NA 2022
- RPID 2021
- Fundamental
- Price
- NA $5.07
- RPID $3.11
- Analyst Decision
- NA
- RPID Strong Buy
- Analyst Count
- NA 0
- RPID 2
- Target Price
- NA N/A
- RPID $8.00
- AVG Volume (30 Days)
- NA 217.2K
- RPID 70.7K
- Earning Date
- NA 08-15-2025
- RPID 10-31-2025
- Dividend Yield
- NA N/A
- RPID N/A
- EPS Growth
- NA N/A
- RPID N/A
- EPS
- NA N/A
- RPID N/A
- Revenue
- NA $3,369,693.00
- RPID $30,289,000.00
- Revenue This Year
- NA N/A
- RPID $16.63
- Revenue Next Year
- NA N/A
- RPID $21.98
- P/E Ratio
- NA N/A
- RPID N/A
- Revenue Growth
- NA N/A
- RPID 22.57
- 52 Week Low
- NA $2.77
- RPID $0.83
- 52 Week High
- NA $31.48
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- NA 47.10
- RPID 57.29
- Support Level
- NA $4.82
- RPID $2.93
- Resistance Level
- NA $5.20
- RPID $3.18
- Average True Range (ATR)
- NA 0.37
- RPID 0.22
- MACD
- NA 0.05
- RPID 0.09
- Stochastic Oscillator
- NA 25.75
- RPID 66.94
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.